Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for BRIACELL THERAP (BCTX : NSDQ)
 
 • Company Description   
BriaCell Therapeutics Corp. is an immuno-oncology focused biotechnology company. It developed a patented whole-cell vaccine, cancer immunotherapy technology called the `BriaVax` vaccine for cancer. The company's technology consists of Bria-IMT(TM), Bria-OTS(TM) and BriaDx(TM) which are in clinical stage. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Number of Employees: 18

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.91 Daily Weekly Monthly
20 Day Moving Average: 315,134 shares
Shares Outstanding: 6.78 (millions)
Market Capitalization: $19.72 (millions)
Beta: 1.27
52 Week High: $21.45
52 Week Low: $2.78
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -12.87% -17.59%
12 Week -27.43% -39.12%
Year To Date -65.65% -67.82%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
235 15th Street Suite 300
-
WEST VANCOUVER,A1 V7T 2X1
CAN
ph: 604-921-1810
fax: 604-921-1898
investors@briacell.com https://briacell.com
 
 • General Corporate Information   
Officers
William V. Williams - President; Chief Executive Officer; and Director
Jamieson Bondarenko - Chairman of the Board of Directors
Gadi Levin - Chief Financial Officer and Corporate Secretary
Vaughn C. Embro-Pantalony - Director
Marc Lustig - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 107930208
SIC: 2834
Fiscal Year
Fiscal Year End: July
Last Reported Quarter: 04/01/25
Next Expected EPS Date: 10/27/25
Share - Related Items
Shares Outstanding: 6.78
Most Recent Split Date: 1.00 (0.07:1)
Beta: 1.27
Market Capitalization: $19.72 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.39 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.63 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 10/27/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.65
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -199.44%
vs. Previous Quarter: 29.61%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
04/30/25 - -479.97
01/31/25 - -
10/31/24 - -
ROA
04/30/25 - -182.26
01/31/25 - -145.56
10/31/24 - -191.19
Current Ratio
04/30/25 - 3.41
01/31/25 - 1.37
10/31/24 - 1.65
Quick Ratio
04/30/25 - 3.41
01/31/25 - 1.37
10/31/24 - 1.65
Operating Margin
04/30/25 - -
01/31/25 - -
10/31/24 - -
Net Margin
04/30/25 - -
01/31/25 - -
10/31/24 - -
Pre-Tax Margin
04/30/25 - -
01/31/25 - -
10/31/24 - -
Book Value
04/30/25 - 1.76
01/31/25 - 0.87
10/31/24 - 1.54
Inventory Turnover
04/30/25 - -
01/31/25 - -
10/31/24 - -
Debt-to-Equity
04/30/25 - 0.00
01/31/25 - 0.00
10/31/24 - 0.00
Debt-to-Capital
04/30/25 - 0.00
01/31/25 - 0.00
10/31/24 - 0.00
 

Powered by Zacks Investment Research ©